Results 211 to 220 of about 2,234,624 (258)

Targeting the NAD+/SIRT1 axis: A metabolic strategy to overcome oxaliplatin resistance in colorectal cancer. [PDF]

World J Gastroenterol
Hussain MS, Jakhmola V, Goyal K, Rekha A, Sultana A, Ali H, Gupta G.   +6 more
europepmc   +1 more source

Host–Microbe Mechanisms of Fusobacterium nucleatum in Colorectal Cancer

Molecular Oral Microbiology, Volume 41, Issue 5, Page 258-265, October 2026.
Fusobacterium nucleatum and colorectal cancer. ABSTRACT The oral‐derived pathobiont Fusobacterium nucleatum has increasingly been implicated in colorectal cancer (CRC) progression through its ability to modulate inflammatory, immunological, and molecular pathways. F.
Hadda Lyzandra Austríaco Leite, Fernanda Ferreira Lopes   +1 more
wiley   +1 more source

An integrative analysis of transcriptome, methylome and single-cell RNA sequencing data identifies UBE2H as a marker of oxaliplatin resistance in colorectal cancer. [PDF]

Cancer Cell Int
Fang J, Zhu Q, Hong B, Li X, Wang H.
europepmc   +1 more source

Ellagic Acid Enhances RSL3‐Induced Ferroptosis by Inhibiting the Nrf2/HO‐1 Signaling Pathway in Pancreatic Ductal Adenocarcinoma

The FASEB Journal, Volume 40, Issue 18, 30 September 2026.
Ellagic acid potentiates RSL3‐induced ferroptosis in PANC‐1 by suppressing the Nrf2/HO‐1 antioxidant defense axis via p38 MAPK activation and Keap1 upregulation. In PDAC cells, constitutive Nrf2/HO‐1 signaling establishes a robust antioxidant shield (GPX4, HO‐1) that limits lipid ROS accumulation and confers ferroptosis resistance.
Jianhua Bai, Yihe Dai, Chern Ein Oon, Pingping Hu, Jia Luo, Jiang Han, Liman Yang, Amirabas Bostani, Zhenhao Fei, Yun Jin   +9 more
wiley   +1 more source

DIRAS1 Drives Oxaliplatin Resistance in Colorectal Cancer via PHB1-Mediated Mitochondrial Homeostasis. [PDF]

Biology (Basel)
Long M, Ouyang Q, Wen J, Zeng X, Xu Z, Zhong S, Huang C, Luo JL.   +7 more
europepmc   +1 more source

DEPP1: A prognostic biomarker linked to stroma‑rich and immunosuppressive microenvironment, promoting oxaliplatin resistance in gastric cancer. [PDF]

Oncol Rep
Qiu X, Pan T, Kuang T, Shen Y, Zheng Y, Geng H, Ni B, Xia X, Zhu C, Zhang Z, Cao H, Tu L.   +11 more
europepmc   +1 more source

[Ethanol promotes oxaliplatin resistance in colorectal cancer by activating the TGF‑β/Smad/P21 signaling axis]. [PDF]

Nan Fang Yi Ke Da Xue Xue Bao
Tan B, Weng N, Zeng W, Gu J, Weng L, Wen H, Xiao H, Zheng K.   +7 more
europepmc   +1 more source

Alectinib and SALL4-Targeted Fatty Acid Oxidation: A Strategy to Combat Oxaliplatin Resistance in Gastric Cancer. [PDF]

Turk J Gastroenterol
Xiao Y, Fang K, Liao J, Zhou H, Zhu W, Liu Z, Ouyang H, Liu K.   +7 more
europepmc   +1 more source

NAD+/SIRT1 pathway regulates glycolysis to promote oxaliplatin resistance in colorectal cancer. [PDF]

World J Gastroenterol
Niu YR, Xiang MD, Yang WW, Fang YT, Qian HL, Sun YK.   +5 more
europepmc   +1 more source

RETRACTION: LncRNA NR2F1-AS1 Regulates Hepatocellular Carcinoma Oxaliplatin Resistance by Targeting ABCC1 via miR-363. [PDF]

J Cell Mol Med
europepmc   +1 more source